Last Price
13.20
Today's Change
+0.055 (0.41%)
Day's Change
13.17 - 13.71
Trading Volume
148,360
Market Cap
1 Billion
Shares Outstanding
127 Million
Avg Volume
546,749
Avg Price (50 Days)
13.00
Avg Price (200 Days)
15.74
PE Ratio
13.20
EPS
1.00
Earnings Announcement
14-Feb-2025
Previous Close
13.15
Open
13.44
Day's Range
13.17 - 13.71
Year Range
10.9 - 24.0
Trading Volume
148,411
1 Day Change
0.38%
5 Day Change
-6.38%
1 Month Change
11.39%
3 Month Change
-20.19%
6 Month Change
-17.19%
Ytd Change
7.76%
1 Year Change
-42.61%
3 Year Change
234.18%
5 Year Change
361.54%
10 Year Change
288.24%
Max Change
131.17%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.